Rhinitis Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibr

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Rhinitis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Rhinitis Market.

The Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Rhinitis Pipeline Report: https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Rhinitis treatment therapies with a considerable amount of success over the years.
• Rhinitis companies working in the treatment market are Funpep, Inimmune, Chia Tai Tianqing Pharmaceutical Group, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibrahim Pharmaceuticals, Regeneron, Revelation Biosciences, Qyuns Therapeutics, Hyloris Pharmaceuticals, and others, are developing therapies for the Rhinitis treatment
• Emerging Rhinitis therapies in the different phases of clinical trials are- FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN1908-1909, Glycopyranosyl lipid adjuvant, QX 005N, HY-083, and others are expected to have a significant impact on the Rhinitis market in the coming years.
• In November 2022, A TRPV1 agonist delivered as an intranasal spray by Hyloris Pharmaceuticals SA has been developed as a treatment for idiopathic rhinitis. In idiopathic rhinitis, the nasal mucosa exhibits an overabundance of TRPV1, which results in nasal obstruction, rhinorrhea (commonly known as a runny nose), and/or sneezing.
• In June 2022, According to Revelation Biosciences Inc., recruitment and dosing for its Phase Ib CLEAR clinical research to assess the safety and effectiveness of intranasal REVTx-99b for the treatment of allergic rhinitis have been completed. A patented intranasal formulation called REVTx-99b is currently being developed to treat the signs and symptoms of allergic rhinitis, such as persistent nasal congestion. In a Phase I clinical investigation, the active ingredient was demonstrated to upregulate a protein that competes with the native eotaxin receptor, CCR3, preventing eotaxin from attracting eosinophils and basophils. This decreases the recruitment of Th2 cells and dampens the allergic response.
• In May 2022, In accordance with US FDA IND regulatory requirements, NeuCen BioMed Co. Ltd. has hired BioKey, a wholly-owned subsidiary of ABVC Biopharma, Inc. with headquarters in Fremont, California, to oversee the completion of two NeuCen drug products, CEN501 and NEU001, in Phase II clinical studies. Patients with allergic rhinitis caused by mites might utilise CEN501, a nasal strip medication, as local nasal immunotherapy (LNIT). Two early clinical trials in Taiwan have examined and validated the clinical efficacy and safety of CEN501.
• In April 2021, Collaboration between NTS hub S., Inmunotek S.L., and BioClever 2005 S.L.A prospective, randomised, placebo-controlled, multi-center project was started to assess the efficacy and safety of subcutaneous immunotherapy employing a combination of grasses and mites at suitable doses with monotherapy.
• Inimmune is working on a quick disease-modifying medication that does not call for the allergen's identification. INI-2004 is an immunotherapy that binds and activates Toll-like receptor 4, regardless of the presence of allergens. INI-2004 significantly decreased measurements of AR in pre-clinical animal models when administered orally. These include eosinophil inflow, airway resistance, and the release of cytokines that indicate an allergic reaction. Clinical trials in phase I will start in Q2 2023.

Rhinitis Overview
A pattern of symptoms brought on by nasal inflammation and/or nasal mucosal failure is referred to as rhinitis. It is an umbrella entity that encompasses a wide range of distinct subtypes, some of which defy full classification. Numerous etiologic factors, including infections, immediate-type allergic reactions, inhaled irritants, medicines, hormonal imbalances, and neural system dysfunction, may contribute to rhinitis.

Get a Free Sample PDF Report to know more about Rhinitis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Rhinitis Drugs Under Different Phases of Clinical Development Include:
• FPP004: Funpep
• INI 2004: Inimmune
• TQC 3564: Chia Tai Tianqing Pharmaceutical Group
• ILT-101: Iltoo Pharma
• IRL201104: Revolo Biotherapeutics
• PA9159: Anhui Palo Alto Pharmaceuticals
• MM09-MG01: Inmunotek SL
• AI201901: Abdi Ibrahim Pharmaceuticals
• REGN1908-1909: Regeneron
• Glycopyranosyl lipid adjuvant: Revelation Biosciences
• QX 005N: Qyuns Therapeutics
• HY-083: Hyloris Pharmaceuticals

Rhinitis Route of Administration
Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

Rhinitis Molecule Type
Rhinitis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Rhinitis Pipeline Therapeutics Assessment
• Rhinitis Assessment by Product Type
• Rhinitis By Stage and Product Type
• Rhinitis Assessment by Route of Administration
• Rhinitis By Stage and Route of Administration
• Rhinitis Assessment by Molecule Type
• Rhinitis by Stage and Molecule Type

DelveInsight's Rhinitis Report covers around 35+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Rhinitis product details are provided in the report. Download the Rhinitis pipeline report to learn more about the emerging Rhinitis therapies at:
https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Rhinitis Therapeutics Market include:
Key companies developing therapies for Rhinitis are - Regeneron, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inc., Abdi Ibrahim Pharmaceuticals, Inmunotek, Iltoo Pharma, Advagene Biopharma Co. Ltd., AOBiome LLC, Emergo Therapeutics, Inimmune, Paradigm Biopharmaceuticals, Siolta Therapeutics, Revelation Biosciences Inc., Allergy Therapeutics, NeuCen BioMed, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Marinomed Biotech, Dobecure, Hyloris Pharmaceuticals, Qyuns Therapeutics, Worg Pharmaceuticals, Altamira Therapeutics, DC4U, Desentum, Funpep, and others.

Rhinitis Pipeline Analysis:
The Rhinitis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Rhinitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Rhinitis Treatment.
• Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Rhinitis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Rhinitis drugs and therapies-
https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Rhinitis Pipeline Market Drivers
• Increase in the prevalence of various form of rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Rhinitis Market.

Rhinitis Pipeline Market Barriers
• However, high competition from generic drugs, side-effects associated with the rhinitis treatment and other factors are creating obstacles in the Rhinitis Market growth.

Scope of Rhinitis Pipeline Drug Insight
• Coverage: Global
• Key Rhinitis Companies: Funpep, Inimmune, Chia Tai Tianqing Pharmaceutical Group, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharmaceuticals, Inmunotek SL, Abdi Ibrahim Pharmaceuticals, Regeneron, Revelation Biosciences, Qyuns Therapeutics, Hyloris Pharmaceuticals, and others
• Key Rhinitis Therapies: FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN1908-1909, Glycopyranosyl lipid adjuvant, QX 005N, HY-083, and others
• Rhinitis Therapeutic Assessment: Rhinitis current marketed and Rhinitis emerging therapies
• Rhinitis Market Dynamics: Rhinitis market drivers and Rhinitis market barriers

Request for Sample PDF Report for Rhinitis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/rhinitis-pipeline?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Rhinitis Report Introduction
2. Rhinitis Executive Summary
3. Rhinitis Overview
4. Rhinitis- Analytical Perspective In-depth Commercial Assessment
5. Rhinitis Pipeline Therapeutics
6. Rhinitis Late Stage Products (Phase II/III)
7. Rhinitis Mid Stage Products (Phase II)
8. Rhinitis Early Stage Products (Phase I)
9. Rhinitis Preclinical Stage Products
10. Rhinitis Therapeutics Assessment
11. Rhinitis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Rhinitis Key Companies
14. Rhinitis Key Products
15. Rhinitis Unmet Needs
16 . Rhinitis Market Drivers and Barriers
17. Rhinitis Future Perspectives and Conclusion
18. Rhinitis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Rhinitis Market https://www.delveinsight.com/report-store/rhinitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rhinitis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Rhinitis Epidemiology https://www.delveinsight.com/report-store/rhinitis-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Rhinitis Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports:

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.